Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jul 8;26(14):6549.
doi: 10.3390/ijms26146549.

Lower Initial Insulin-like Growth Factor-Binding Protein-3 Concentrations May Reflect Immune Suppression and Predict Increased Risk of Sepsis-Related Mortality

Affiliations

Lower Initial Insulin-like Growth Factor-Binding Protein-3 Concentrations May Reflect Immune Suppression and Predict Increased Risk of Sepsis-Related Mortality

Filippo Mearelli et al. Int J Mol Sci. .

Abstract

Insulin-like growth factor-binding protein-3 (IGFBP-3) plays a vital role in cellular growth, development, and survival. Incorporating IGFBP-3 into baseline prognostic evaluations may enhance the prediction of mortality in patients with sepsis. In this study, serum levels of IGFBP-3, C-reactive protein, procalcitonin, lactate, interleukin-6, and mid-regional pro-adrenomedullin were measured upon admission to the internal medicine unit (IMU) in 139 patients with microbiologically confirmed sepsis. The objectives were as follows: (1) to classify septic patient phenotypes based on optimal thresholds of independent prognostic biomarkers and (2) to evaluate whether these biomarkers improve the predictive accuracy of a clinical model (Model 1), which includes the clinical predictors of 1-year mortality. Age, sequential organ failure assessment (SOFA) score, multiple sources of infection, and IGFBP-3 levels independently predicted 1-year mortality. Patients with IGFBP-3 levels below 10.64 had significantly lower median body temperature (p = 0.008), reduced lymphocyte count (p = 0.001), and higher 1-year mortality (p < 0.001). Model 1 included age, SOFA score, and the presence of multiple sources of sepsis as predictor variables. Model 2 incorporated the same variables as Model 1, with the addition of IGFBP-3 levels. When comparing their prognostic performance, Model 2 demonstrated superior predictive accuracy for mortality at 60, 90, and 365 days following admission to the IMU. Low IGFBP-3 levels at IMU admission are strongly associated with worse outcomes in septic patients, supporting its potential use as a prognostic biomarker.

Keywords: gut dysfunction; immune suppression; insulin-like growth factor; insulin-like growth factor-binding protein-3; interleukin-6; lactate; mid-regional pro-adrenomedullin; procalcitonin; sepsis.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
(a) Kaplan–Meier curves of freedom from 1-year mortality for patients grouped according to the best prognostic cut-off of insulin-like growth factor-binding protein-3 levels. Abbreviations: IGFBP-3 = insulin-like growth factor-binding protein-3 (expressed as Log levels), IMU = internal medicine unit. Legend: Log-rank < 0.001. (b) Kaplan–Meier curves of freedom from 30-day mortality for patients grouped according to the best prognostic cut-off of insulin-like growth factor-binding protein-3 levels. Abbreviations: IGFBP-3 insulin-like growth factor-binding protein-3 (expressed as Log levels), IMU = internal medicine unit. Legend: Log-rank = 0.007. (c) Time-dependent receiver operating characteristic curves of Model 1 and Model 2 for predicting mortality up to 1 year from internal medicine unit admission. Abbreviations: AUC = area under the receiver operating characteristic curve. Legend: Model 1 includes age, SOFA score, and multiple sources of sepsis. Model 2 includes age, SOFA score, multiple sources of sepsis, and insulin-like growth factor-binding protein-3 levels expressed as Log levels. Time is expressed in days from internal medicine unit admission.
Figure 1
Figure 1
(a) Kaplan–Meier curves of freedom from 1-year mortality for patients grouped according to the best prognostic cut-off of insulin-like growth factor-binding protein-3 levels. Abbreviations: IGFBP-3 = insulin-like growth factor-binding protein-3 (expressed as Log levels), IMU = internal medicine unit. Legend: Log-rank < 0.001. (b) Kaplan–Meier curves of freedom from 30-day mortality for patients grouped according to the best prognostic cut-off of insulin-like growth factor-binding protein-3 levels. Abbreviations: IGFBP-3 insulin-like growth factor-binding protein-3 (expressed as Log levels), IMU = internal medicine unit. Legend: Log-rank = 0.007. (c) Time-dependent receiver operating characteristic curves of Model 1 and Model 2 for predicting mortality up to 1 year from internal medicine unit admission. Abbreviations: AUC = area under the receiver operating characteristic curve. Legend: Model 1 includes age, SOFA score, and multiple sources of sepsis. Model 2 includes age, SOFA score, multiple sources of sepsis, and insulin-like growth factor-binding protein-3 levels expressed as Log levels. Time is expressed in days from internal medicine unit admission.

References

    1. Rudd K.E., Johnson S.C., Agesa K.M., Shackelford K.A., Tsoi D., Kievlan D.R., Colombara D.V., Ikuta K.S., Kissoon N., Reinhart K.K., et al. Global, regional, and national sepsis incidence and mortality, 1990–2017: Analysis for the Global Burden of Disease Study. Lancet. 2020;395:200–211. doi: 10.1016/S0140-6736(19)32989-7. - DOI - PMC - PubMed
    1. Evans L., Rhodes A., Alhazzani W., Antonelli M., Coopersmith C.M., French C., Machado F.R., Mcintyre L., Ostermann M., Prescott H.C., et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021. Crit. Care Med. 2021;49:e1063–e1143. doi: 10.1097/CCM.0000000000005337. - DOI - PubMed
    1. Pierrakos C., Velissaris D., Bisdorff M., Marshall J.C., Vincent J.-L. Biomarkers of sepsis: Time for a reappraisal. Crit. Care. 2020;24:287. doi: 10.1186/s13054-020-02993-5. - DOI - PMC - PubMed
    1. Pierrakos C., Vincent J.-L. Sepsis biomarkers: A review. Crit. Care. 2010;14:R15. doi: 10.1186/cc8872. - DOI - PMC - PubMed
    1. Barichello T., Generoso J.S., Singer M., Dal-Pizzol F. Biomarkers for sepsis: More than just fever and leukocytosis-a narrative review. Crit. Care. 2022;26:14. doi: 10.1186/s13054-021-03862-5. - DOI - PMC - PubMed